IL27 report

I. Expression across cell types

Insufficient scRNA-seq data for expression of IL27 at single-cell level.

II. Expression across tissues

sc-RNAseq data

Insufficient scRNA-seq data for expression of IL27 at tissue level.

III. Associated gene sets

GO_0007165Biological processsignal transduction
GO_0042129Biological processregulation of T cell proliferation
GO_0032729Biological processpositive regulation of type II interferon production
GO_0006954Biological processinflammatory response
GO_0140459Biological processresponse to Gram-positive bacterium
GO_0002230Biological processpositive regulation of defense response to virus by host
GO_0045087Biological processinnate immune response
GO_0045625Biological processregulation of T-helper 1 cell differentiation
GO_0005615Cellular componentextracellular space
GO_0009986Cellular componentcell surface
GO_0005788Cellular componentendoplasmic reticulum lumen
GO_0005829Cellular componentcytosol
GO_0005576Cellular componentextracellular region
GO_0045523Molecular functioninterleukin-27 receptor binding
GO_0005102Molecular functionsignaling receptor binding
GO_0005515Molecular functionprotein binding
GO_0005125Molecular functioncytokine activity

IV. Literature review

[source]
Gene nameIL27
Protein nameInterleukin 27
Interleukin-27 subunit alpha (IL-27 subunit alpha) (IL-27-A) (IL27-A) (Interleukin-30) (p28)
SynonymsIL30
IL27A
DescriptionFUNCTION: Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of pro-inflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses pro-inflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replication. .

AccessionsENST00000568075.1
Q8NEV9
H3BQY2
ENST00000356897.1